Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 277-283

  Enghard, Philipp ^a   Rieder, Claudia ^a   Kopetschke, Katharina ^a   Klocke, J R ^a   Undeutsch, Reinmar ^a,b   Biesen, Robert ^a   Dragun, Duska ^a   Gollasch, Maik ^a   Schneider, Udo ^a   Aupperle, Karlfried ^a   Humrich, Jens Y ^a   Hiepe, Falk ^a   Backhaus, Marina ^a   Radbruch, A H ^b   Burmester, Gerd R ^a   Riemekasten, Gabriela ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS; YOUNG ADULT;

AUTOIMMUNE DISEASES; INFLAMMATION; LUPUS NEPHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELLS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINE; YOUNG ADULT;

EID: 84889686439     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202784     Document Type: Article

References (27)

1. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994;330:1871-9.
2. Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009;36:63-7.
3. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182.
4. Faurschou M, Starklint H, Halberg P, et al. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006;33:1563-9. (Pubitemid 44168828)
5. Esdaile JM, Joseph L, MacKenzie T, et al. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994;21:2046-51. (Pubitemid 24352349)
6. Fiehn C, Hajjar Y, Mueller K, et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003;62:435-9. (Pubitemid 36469735)
7. Preda A, Van Dijk LC, Van Oostaijen JA, et al. Complication rate and diagnostic yield of 515 consecutive ultrasound-guided biopsies of renal allografts and native kidneys using a 14-gauge Biopty gun. Eur Radiol 2003;13:527-30. (Pubitemid 36790526)
8. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42. (Pubitemid 36554532)
9. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008;58:1136-45. (Pubitemid 351564017)
10. Enghard P, Humrich JY, Rudolph B, et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum 2009;60:199-206.
11. Dolff S, Abdulahad WH, van Dijk MC, et al. Urinary T cells in active lupus nephritis show an effector memory phenotype. Ann Rheum Dis 2010;69:2034-41.
12. Yu F, Wu LH, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010;77:820-9.
13. Park MH, D'Agati V, Appel GB, et al. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986;44:309-19. (Pubitemid 17178104)
14. Esdaile JM, Levinton C, Federgreen W, et al. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 1989;72:779-833. (Pubitemid 19230673)
15. Boucher A, Droz D, Adafer E, et al. Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates. Kidney Int 1986;29:1043-9. (Pubitemid 16122576)
16. Caligaris-Cappio F, Bergui L, Tesio L, et al. HLA-Dr+ T cells of the Leu 3 (helper) type infiltrate the kidneys of patients with systemic lupus erythematosus. Clin Exp Immunol 1985;59:185-9. (Pubitemid 15197412)
17. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797-808.
18. Grootscholten C, Bajema IM, Florquin S, et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol Dial Transplant 2008;23:223-30. (Pubitemid 351767369)
19. Mok CC. Biomarkers for lupus nephritis: a critical appraisal. J Miomed Biotechnol 2010;2010:638413.
20. Enghard P, Riemekasten G. Immunology and the diagnosis of lupus nephritis. Lupus 2009;18:287-90.
21. Reyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011;40:138-50.
22. Singh S, Wu T, Xie C, et al. Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res Ther 2012;14:R164.
23. Rovin BH, Song H, Birmingham DJ, et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005;16:467-73. (Pubitemid 41725143)
24. Wu T, Xie C, Wang HW, et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007;179:7166-75.
25. Schwartz N, Rubinstein T, Burkly LC, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009;11:R143.
26. Schwartz N, Su L, Burkly LC, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27:242-50. (Pubitemid 46206104)
27. Avihingsanon Y, Phumesin P, Benjachat T, et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006;69:747-53. (Pubitemid 43237645)